Mr. Brown has been Chief Executive Officer of Arteriocyte, since becoming its first employee in 2004. To date, he has raised $60 Million in capital for the company, and has built a team of 76 employees worldwide that hold true to the company’s vision of “helping patients heal faster”.
Arteriocyte’s early cell therapy development targeted concentrating and delivering marrow-derived stem cells to myocardial tissues in patients with chronic ischemia. In October of 2007, the six employees of Arteriocyte partnered with DW Healthcare Partners to create Arteriocyte Medical Systems Inc., to acquire the Magellan rapid bedside fractionation device brand from Medtronic. The Magellan acquisition created a platform for the company to aspirate and concentrate tissues in the operating room for application to injured tissue. Today Arteriocyte enables over 5,000 musculoskeletal and cardiovascular procedures a month, and has multiple clinical development programs targeting chronic wounds, burn debridement, and infection control. Arteriocyte’s development programs focus on triggering repair of both acute and chronically damaged tissues in order to help accelerate repair.
Mr. Brown has over 24 years of experience in the health care industry, including twelve years of operational experience at Schering Plough where he had P&L responsibility for one of the first billion dollar pharmaceutical franchises in the U.S., (CLARITIN), and two years at a stem cell therapy company focused on developing umbilical cord blood stem cells to treat leukemia. His extensive management experience includes business development and operations management, as well as sales and marketing, and disease management. Don holds a Bachelor’s in Business Administration degree from the University of Notre Dame.